Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects

Suzy E. Meijer*, Ora Halutz, Amos Adler, Katya Levytskyi, Luba Tau, Michal Dekel, Ronit Cohen-Poradosu, Evgene Katchman, David Shasha, Jacob Ablin, Guy Choshen, Giris Jacob, Asaf Wasserman, Merav Ingbir, Yael C. Cohen, Chava Perry, Ron Ram, Yair Herishanu, Yael Bar On, Elma van ThijnNatalie Rutsinsky, Sheri Harari, Adi Stern, Ronen Ben-Ami, Yael Paran

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects'. Together they form a unique fingerprint.

Medicine & Life Sciences